Recursion Pharmaceuticals (RXRX) shares recently closed at US$3.98, with the stock showing a negative return over the past month and past 3 months, which may prompt investors to reassess its current ...

Meara covers streaming service news for CNET. She graduated from the University of Texas at Austin with a degree in journalism. When she's not writing, she likes to dote over her cat, sip black coffee ...

Prompted Playlist will roll out to Spotify Premium subscribers in the US and Canada by the end of January. (Spotify) Ahead of its upcoming price hike, Spotify is rolling out a more advanced AI ...

Spotify is rolling out a new Prompted Playlist feature. It'll help you create a playlist by describing the vibe you're looking for. It is now available in beta for Premium users in the US and Canada.

Jake Peterson is Lifehacker’s Tech Editor, and has been covering tech news and how-tos for nearly a decade. His team covers all things technology, including AI, smartphones, computers, game consoles, ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

With its playlist chatbot, Spotify says you could ‘curate your next Discover Weekly, exactly the way you want it.’ With its playlist chatbot, Spotify says you could ‘curate your next Discover Weekly ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

This is this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, leaders and investors straight to your inbox. Click here to get on the ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...